APNIMED

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders. Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has serious consequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles. Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions. Apnimed was founded in 2017 and is located in Cambridge, Massachusetts.